AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer

Yi Xie, Martin J. Hicks, Stephen M. Kaminsky, Malcolm A.S. Moore, Ronald Crystal, Arash Rafii Tabrizi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Rationale Anti-angiogenesis therapies such as bevacizumab, the monoclonal antibody to vascular endothelial growth factor (VEGF), have been used against ovarian cancer, but transient and low peritoneal drug levels are likely a factor in treatment failure. We hypothesized that a single administration of adeno-associated virus (AAV)-mediated intraperitoneal expression of bevacizumab would direct persistent expression and suppress growth and metastasis of ovarian cancer.

Methods AAVrh.10BevMab, a rhesus serotype 10 adeno-associated viral vector coding for bevacizumab, was evaluated for the capacity of a single intraperitoneal administration to persistently suppress peritoneal tumor growth in an intraperitoneal model of ovarian carcinomatosis with human ovarian cancer cells in nude immunodeficient mice.

Results The data demonstrates that AAVrh10.BevMab mediates persistent and high levels of bevacizumab in the peritoneal cavity following a single intraperitoneal administration in mice. In AAVrh10.BevMab treated A2780 human ovarian cancer-bearing mice, tumor growth was significantly suppressed (p < 0.05) and the area of blood vessels in the tumor was decreased (p < 0.04). Survival of mice with A2780 xenografts or SK-OV3 xenografts was greatly prolonged in the presence of AAVrh10.BevMab (p < 0.001). Administration of AAVrh10.BevMab 4 days after A2780-luciferase cell implantation reduced tumor growth (p < 0.01) and increased mouse survival (p < 0.0001). Combination of AAVrh10.BevMab with cytotoxic reagents paclitaxel or topotecan proved to be more effective in increasing survival than treatment with cytotoxic reagent alone.

Conclusion A single administration of AAVrh10.BevMab provides sustained and high local expression of bevacizumab in the peritoneal cavity, and significantly suppresses peritoneal carcinomatosis and increases survival in an ovarian cancer murine model.

Original languageEnglish
Pages (from-to)325-332
Number of pages8
JournalGynecologic Oncology
Volume135
Issue number2
DOIs
Publication statusPublished - 1 Nov 2014

Fingerprint

Dependovirus
Ovarian Neoplasms
Growth
Peritoneal Cavity
Neoplasms
Heterografts
Vascular Tissue Neoplasms
Topotecan
Carcinoma
Therapeutics
Survival
Paclitaxel
Luciferases
Treatment Failure
Nude Mice
Vascular Endothelial Growth Factor A
Monoclonal Antibodies
Bevacizumab
Neoplasm Metastasis
Pharmaceutical Preparations

Keywords

  • AAV vector
  • Anti-angiogenesis
  • Bevacizumab
  • Gene therapy
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. / Xie, Yi; Hicks, Martin J.; Kaminsky, Stephen M.; Moore, Malcolm A.S.; Crystal, Ronald; Tabrizi, Arash Rafii.

In: Gynecologic Oncology, Vol. 135, No. 2, 01.11.2014, p. 325-332.

Research output: Contribution to journalArticle

Xie, Yi ; Hicks, Martin J. ; Kaminsky, Stephen M. ; Moore, Malcolm A.S. ; Crystal, Ronald ; Tabrizi, Arash Rafii. / AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. In: Gynecologic Oncology. 2014 ; Vol. 135, No. 2. pp. 325-332.
@article{860865cfa2ad40619eeb7dc861c4d917,
title = "AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer",
abstract = "Rationale Anti-angiogenesis therapies such as bevacizumab, the monoclonal antibody to vascular endothelial growth factor (VEGF), have been used against ovarian cancer, but transient and low peritoneal drug levels are likely a factor in treatment failure. We hypothesized that a single administration of adeno-associated virus (AAV)-mediated intraperitoneal expression of bevacizumab would direct persistent expression and suppress growth and metastasis of ovarian cancer.Methods AAVrh.10BevMab, a rhesus serotype 10 adeno-associated viral vector coding for bevacizumab, was evaluated for the capacity of a single intraperitoneal administration to persistently suppress peritoneal tumor growth in an intraperitoneal model of ovarian carcinomatosis with human ovarian cancer cells in nude immunodeficient mice.Results The data demonstrates that AAVrh10.BevMab mediates persistent and high levels of bevacizumab in the peritoneal cavity following a single intraperitoneal administration in mice. In AAVrh10.BevMab treated A2780 human ovarian cancer-bearing mice, tumor growth was significantly suppressed (p < 0.05) and the area of blood vessels in the tumor was decreased (p < 0.04). Survival of mice with A2780 xenografts or SK-OV3 xenografts was greatly prolonged in the presence of AAVrh10.BevMab (p < 0.001). Administration of AAVrh10.BevMab 4 days after A2780-luciferase cell implantation reduced tumor growth (p < 0.01) and increased mouse survival (p < 0.0001). Combination of AAVrh10.BevMab with cytotoxic reagents paclitaxel or topotecan proved to be more effective in increasing survival than treatment with cytotoxic reagent alone.Conclusion A single administration of AAVrh10.BevMab provides sustained and high local expression of bevacizumab in the peritoneal cavity, and significantly suppresses peritoneal carcinomatosis and increases survival in an ovarian cancer murine model.",
keywords = "AAV vector, Anti-angiogenesis, Bevacizumab, Gene therapy, Ovarian cancer",
author = "Yi Xie and Hicks, {Martin J.} and Kaminsky, {Stephen M.} and Moore, {Malcolm A.S.} and Ronald Crystal and Tabrizi, {Arash Rafii}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.ygyno.2014.07.105",
language = "English",
volume = "135",
pages = "325--332",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer

AU - Xie, Yi

AU - Hicks, Martin J.

AU - Kaminsky, Stephen M.

AU - Moore, Malcolm A.S.

AU - Crystal, Ronald

AU - Tabrizi, Arash Rafii

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Rationale Anti-angiogenesis therapies such as bevacizumab, the monoclonal antibody to vascular endothelial growth factor (VEGF), have been used against ovarian cancer, but transient and low peritoneal drug levels are likely a factor in treatment failure. We hypothesized that a single administration of adeno-associated virus (AAV)-mediated intraperitoneal expression of bevacizumab would direct persistent expression and suppress growth and metastasis of ovarian cancer.Methods AAVrh.10BevMab, a rhesus serotype 10 adeno-associated viral vector coding for bevacizumab, was evaluated for the capacity of a single intraperitoneal administration to persistently suppress peritoneal tumor growth in an intraperitoneal model of ovarian carcinomatosis with human ovarian cancer cells in nude immunodeficient mice.Results The data demonstrates that AAVrh10.BevMab mediates persistent and high levels of bevacizumab in the peritoneal cavity following a single intraperitoneal administration in mice. In AAVrh10.BevMab treated A2780 human ovarian cancer-bearing mice, tumor growth was significantly suppressed (p < 0.05) and the area of blood vessels in the tumor was decreased (p < 0.04). Survival of mice with A2780 xenografts or SK-OV3 xenografts was greatly prolonged in the presence of AAVrh10.BevMab (p < 0.001). Administration of AAVrh10.BevMab 4 days after A2780-luciferase cell implantation reduced tumor growth (p < 0.01) and increased mouse survival (p < 0.0001). Combination of AAVrh10.BevMab with cytotoxic reagents paclitaxel or topotecan proved to be more effective in increasing survival than treatment with cytotoxic reagent alone.Conclusion A single administration of AAVrh10.BevMab provides sustained and high local expression of bevacizumab in the peritoneal cavity, and significantly suppresses peritoneal carcinomatosis and increases survival in an ovarian cancer murine model.

AB - Rationale Anti-angiogenesis therapies such as bevacizumab, the monoclonal antibody to vascular endothelial growth factor (VEGF), have been used against ovarian cancer, but transient and low peritoneal drug levels are likely a factor in treatment failure. We hypothesized that a single administration of adeno-associated virus (AAV)-mediated intraperitoneal expression of bevacizumab would direct persistent expression and suppress growth and metastasis of ovarian cancer.Methods AAVrh.10BevMab, a rhesus serotype 10 adeno-associated viral vector coding for bevacizumab, was evaluated for the capacity of a single intraperitoneal administration to persistently suppress peritoneal tumor growth in an intraperitoneal model of ovarian carcinomatosis with human ovarian cancer cells in nude immunodeficient mice.Results The data demonstrates that AAVrh10.BevMab mediates persistent and high levels of bevacizumab in the peritoneal cavity following a single intraperitoneal administration in mice. In AAVrh10.BevMab treated A2780 human ovarian cancer-bearing mice, tumor growth was significantly suppressed (p < 0.05) and the area of blood vessels in the tumor was decreased (p < 0.04). Survival of mice with A2780 xenografts or SK-OV3 xenografts was greatly prolonged in the presence of AAVrh10.BevMab (p < 0.001). Administration of AAVrh10.BevMab 4 days after A2780-luciferase cell implantation reduced tumor growth (p < 0.01) and increased mouse survival (p < 0.0001). Combination of AAVrh10.BevMab with cytotoxic reagents paclitaxel or topotecan proved to be more effective in increasing survival than treatment with cytotoxic reagent alone.Conclusion A single administration of AAVrh10.BevMab provides sustained and high local expression of bevacizumab in the peritoneal cavity, and significantly suppresses peritoneal carcinomatosis and increases survival in an ovarian cancer murine model.

KW - AAV vector

KW - Anti-angiogenesis

KW - Bevacizumab

KW - Gene therapy

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84913613950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913613950&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2014.07.105

DO - 10.1016/j.ygyno.2014.07.105

M3 - Article

VL - 135

SP - 325

EP - 332

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -